Bionano Genomics(BNGO) - 2022 Q4 - Annual Report

• sales of our securities by us or our stockholders in the future; • trading volume of our securities; • changes in accounting practices; • ineffectiveness of our internal controls; • data breaches of our company, providers, vendors or customers; • regulatory or legal developments in the United States and other countries; • disputes or other developments relating to proprietary rights, including our ability to adequately protect our proprietary rights in our technologies; • significant lawsuits, including p ...